This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ISR Immune System Regulation Holding Résultats passés
Passé contrôle des critères 0/6
Informations clés
-57.2%
Taux de croissance des bénéfices
-28.7%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 0.7% |
| Taux de croissance des recettes | 98.2% |
| Rendement des fonds propres | n/a |
| Marge nette | n/a |
| Dernière mise à jour des bénéfices | 31 Dec 2022 |
Mises à jour récentes des performances passées
Recent updates
We're Not Very Worried About ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Rate
Aug 11
A Look At The Fair Value Of ISR Immune System Regulation Holding AB (publ) (STO:ISR)
Jul 02Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Mar 08Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Nov 18Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Jul 27Here's Why We're Watching ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Situation
Mar 26We Think ISR Immune System Regulation Holding (STO:ISR) Can Afford To Drive Business Growth
Dec 11
Ventilation des recettes et des dépenses
Comment ISR Immune System Regulation Holding gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -213 | 24 | 179 |
| 30 Sep 22 | 0 | -235 | 26 | 203 |
| 30 Jun 22 | 0 | -257 | 29 | 226 |
| 31 Mar 22 | 0 | -168 | 26 | 141 |
| 31 Dec 21 | 0 | -79 | 22 | 56 |
| 30 Sep 21 | 0 | -60 | 20 | 40 |
| 30 Jun 21 | 0 | -41 | 18 | 24 |
| 31 Mar 21 | 0 | -36 | 16 | 20 |
| 31 Dec 20 | 0 | -31 | 14 | 16 |
| 30 Sep 20 | 0 | -29 | 13 | 15 |
| 30 Jun 20 | 0 | -28 | 12 | 14 |
| 31 Mar 20 | 0 | -28 | 13 | 15 |
| 31 Dec 19 | 0 | -29 | 13 | 16 |
| 30 Sep 19 | 0 | -29 | 14 | 15 |
| 30 Jun 19 | 0 | -28 | 14 | 14 |
| 31 Mar 19 | 0 | -25 | 12 | 12 |
| 31 Dec 18 | 0 | -21 | 11 | 10 |
| 30 Sep 18 | 0 | -20 | 13 | 19 |
| 30 Jun 18 | 0 | -18 | 11 | 17 |
| 31 Mar 18 | 0 | -18 | 10 | 14 |
| 31 Dec 17 | 0 | -21 | 9 | 12 |
| 30 Sep 17 | 0 | -30 | 1 | 0 |
| 30 Jun 17 | 0 | -21 | 4 | 0 |
| 31 Mar 17 | 0 | -27 | 2 | 0 |
| 31 Dec 16 | 0 | -14 | 5 | 0 |
Des revenus de qualité: ISR is currently unprofitable.
Augmentation de la marge bénéficiaire: ISR is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ISR is unprofitable, and losses have increased over the past 5 years at a rate of 57.2% per year.
Accélération de la croissance: Unable to compare ISR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ISR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Rendement des fonds propres
ROE élevé: ISR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.